Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature

Pohl, Michael; Werner, Naomi; Münding, Johanna; Tannapfel, Andrea; Graeven, U.; Nickenig, G; Schmiegel, W.; Reinacher‐Schick, Anke

doi:10.1055/s-0031-1281752

Cited by 28 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jalbăet al (2011) showed VEGF-A expression as a poor prognostic marker for CRC in their study (Jalbă et al, 2011). In other study; there was found no correlation between treatment response and VEGF expression within the tumour tissue (Pohl et al, 2011).…”

Section: Discussionmentioning

confidence: 75%

Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy

Kara

Duman²,

Kara³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: No factor has thus far been identified to predict the efficacy of bevacizumab therapy for colorectal cancer. We here therefore studied PTEN, VEGF, HER2 and p53 by immunohistochemistry as possible prognostic and predictive factors. Materials and Methods: A total of 34 retrospectively collected tumor samples were evaluated, all from patients receiving bevacizumab-based regimens. VEGF-A, PTEN, HER2, p53 were assessed and data was compared with clinicopathologic characteristics of patients and the bevacizumab response rate. Results: In this study, the median age of the 34 metastatic colorectal cancer patients was 55.5 (24-75), twelve (35.3%) being women and 22 (64.7%) men. PTEN, VEGF, HER2, p53 expressions were compared with bevacizumab response and other chacteristics of disease. Statistical significant differences were not found between bevacizumab response rates and different expression levels of VEGF, PTEN, HER2 and p53 (respectively p=0.256, p=0.832, p=0.189, p=0.131). However, a survival difference was noted in the VEGF expression negative group (median OS:55 months; 95%CI, 22-88 months) (p=0.01). There was no statistically significant OS difference in other groups (PTEN p=0.6, HER2 p=0.189, p53 p=0.13). Conclusions: We did not find any predictive factor for BV therapy in our study. VEGF negative expression could be an important prognostic factor in metastatic colorectal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 75%

Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy

Kara

Duman²,

Kara³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…A number of potential biomarkers have been evaluated, one after another, in clinical studies, including circulating endothelial progenitor cells (EPCs), circulating endothelial cells (CECs), VEGF serum levels, VEGF tissue expression, serum angiopoietin-2, gene polymorphisms of patients, visceral fat areas, blood pressure, and so on; however, few of them have demonstrated significant predictive value until now [29,30,31,32,33,34]. Moreover, it has been postulated that patients who have elevated pretreatment levels of the plasma soluble form of VEGF receptor (VEGFR)-1 or increased levels of stromal cell-derived factor-1αα (SDF1α) are not likely to benefit from anti-VEGF therapies, which has yet to be verified in further clinical studies [27].…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

Aim: This study investigated the overall and histology subtype-specific results of antiangiogenic agents combined with chemotherapy versus chemotherapy alone for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Methods: Literature retrieval, trial selection, data collection, and statistical analysis were performed according to the Cochrane Handbook. The outcome measures were tumor response rate, progression-free survival (PFS), overall survival (OS), and adverse effects. Results: 13 randomized controlled trials comprising 5,451 patients were included. The meta-analysis showed a higher response rate (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.53-0.74) and a significantly prolonged PFS (hazard ratio (HR) 0.75, 95% CI 0.66-0.85) and OS (HR 0.92, 95% CI 0.86-0.98) in the groups combining antiangiogenic agents with chemotherapy versus the chemotherapy alone groups. In the histology subgroup analysis, treatment with antiangiogenic agents plus chemotherapy significantly improved the RR, PFS, and OS as compared with the chemotherapy groups in patients with nonsquamous NSCLC, but not in those with squamous NSCLC. The risk of grade 3/4 thrombocytopenia, hypertension, bleeding, proteinuria, rash, diarrhea, fatigue, headache, anorexia, and febrile neutropenia was significantly increased in the antiangiogenic agent combination groups as compared with the chemotherapy groups. Conclusion: The use of antiangiogenic agents in addition to chemotherapy is a valid option for the first-line treatment of advanced NSCLC. The benefit is restricted to patients with nonsquamous-cell tumors.

show abstract

“…With respect to chemotherapy (including anti-angiogenic target therapy), a significantly decreased CEPCs concentration was demonstrated in three studies [69,72,76], whereas others reported no significant changes [22,79], and another presented a remarkably higher EPCs level post-treatment [75]. Roodhart et al analyzed the changes in CEPCs in a cohort of patients receiving chemotherapy and found that the increase in EPCs level started a few hours after the initiation of chemotherapy, exceeded to 114 % (95 % CI 78-151 %; NS) after 7 days and continued to increase to 304 % (95 % CI 176-1,431 %; P \ 0.01) on day 21, and was not limited to the regimens applied in the chemotherapy [75].…”

Section: Cepcs As An Indicator Of Treatment Responsementioning

confidence: 99%

“…However, the assessment of these parameters cannot reflect the efficacy immediately and directly, thus necessitating a reliable surrogate biomarker. The potential of CEPCs in the prediction and response monitoring to a therapeutic intervention is determined by distinguishing the impact of various interventions (e.g., surgery, chemotherapy, and radiation) on CEPCs in different cancers, including breast cancer [59,72], head and neck cancer [60], lung cancer [22,54,76], ovarian cancer [61,63], RCC [66,67], colorectal cancer [79], multiple myeloma [69], glioma [56], gastric cancer [74], and mixed types [75] (Table 3). In all studies, the CEPCs levels were quantified by FACS technique, which are not presented in Table 3.…”

Section: Cepcs As An Indicator Of Treatment Responsementioning

confidence: 99%

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

et al. 2014

Med Oncol

View full text Add to dashboard Cite

Human cancers are endowed with sustained vascularization capability, and their growth, invasion, and metastasis are vascularization dependent. Recently, accumulated body of evidence suggests that endothelial progenitor cells (EPCs) can support vasculogenesis and induce angiogenesis through paracrine mechanisms. In addition, numerous clinical studies have revealed the increase in the number of EPCs in the peripheral blood of cancer patients and demonstrated the correlation of circulating EPCs (CEPCs) with the clinical outcomes. This review highlights current enrichment procedures and methods for the detection of CEPCs and different biomarkers to identify CEPCs as well as the functions of EPCs in tumor vascularization. Furthermore, we systematically review available studies on the clinical relevance of CEPCs in cancer patients to explore the potential diagnostic and prognostic values of CEPCs. Although several contrasting results exist, CEPCs can conceivably serve as a promising biomarker for the early diagnosis, prognosis prediction, and treatment response indication in the future. Additionally, further well-designed clinical studies with larger sample size and unique, specific enumeration procedures are warranted to achieve further insight into the clinical implications of CEPCs.

show abstract

Biomarkers of Anti-Angiogenic Therapy in Metastatic Colorectal Cancer (mCRC): Original Data and Review of the Literature

Cited by 28 publications

References 49 publications

Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy

Analysis of PTEN, VEGF, HER2 and P53 Status in Determining Colorectal Cancer Benefit from Bevacizumab Therapy

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

Contact Info

Product

Resources

About